Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...

Related Keywords

Delaware ,United States ,Australia ,Gary Price ,Michael Bober ,Tyra Biosciences ,Amy Conrad ,Todd Harris ,George Melko ,Prnewswire Tyra Biosciences Inc ,Skeletal Dysplasia Program ,Tyra Biosciences Inc ,Drug Administration ,Regulatory Affairs ,Clinical Development ,Exchange Commission ,Nasdaq ,Orphan Drug Designation ,Fibroblast Growth Factor Receptor ,Recent Corporate ,Investigational New Drug ,Advanced Solid Tumors ,Preparation Activities ,Vice President ,Medical Affairs ,Medical Director ,Nemours Children ,Looking Statements ,Private Securities Litigation Reform Act ,Sheet Data ,Months Ended June ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Earnings ,